Cindy Fung, PhD You can read more about your. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Shape Therapeutics, Inc. employs 14 employees. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Our Commitment to Diversity. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Chief Operating Officer. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Also Known As ShapeTX. Working at Shape has been great! Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Glad that you want to get updates from Shape Therapeutics. Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. site you are consenting to these choices. See what employees say it's like to work at Shape Therapeutics. Contact Enter employee name to find & verify emails, phones, social links, etc. Engineering best-in-class. Shape Life! Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". Vice President of Finance, Gary Fortin ", I feel this real connection to the patients were having an impact on. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Sign up for a free account. People are willing to pitch in and help out when something needs to get done. Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Great team culture. No credit card required. By continuing to use this site you are consenting to these choices. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Operator. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Rznomics was founded in 2017 and is based in Yongin-si, South Korea. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Shape Therapeutics has 5 executives. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Im thrilled to join such a talented team of innovative thinkers. Chief Business Officer, Will Krause 11 Shape Therapeutics reviews. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Get the full list, Youre viewing 5 of 9 board members. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Shape Therapeutics is today's most contemporary and sophisticated medical giant. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. The net loss for the full . Its very rewarding. Investors & Media - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging We [] And I don't just mean the science but also on healthcare policy. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. 56% of the management team is White. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. April 20, 2021 08:00 ET ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. We have to be creative; we need to transform the paradigm. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. . 69% of the management team is White. They seem respectful towards one another. . Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Founders Francois Vigneault, John Suliman, Prashant Mali. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Personalize which data points you want to see and create visualizations instantly. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. free lookups / month. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Copyright 2023 CB Information Services, Inc. All rights reserved. from Harvard Law School. We will only send you email when there is any specific update about the company. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Shape Therapeutics, Inc. This is the Shape Therapeutics company profile. 2023 PitchBook. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Last Funding Type Series B. Founded Date Apr 5, 2018. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Shape Therapeutics is a development-stage biotechnology company. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Headquarters Location 219 Terry Ave N Suite 100 Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Shape Therapeutics's Vice President, Head of Research is David Huss. Legal Name Shape Therapeutics, Inc. Company Type For Profit. our sites and services. Get the full list, Youre viewing 5 of 10 investors. July 15, 2021 08:00 ET {{ userNotificationState.getAlertCount('bell') }}. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Chief Scientific Officer, Francois Vigneault Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Seattle, WA 98109, 75 Kneeland Street We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Shape Life! These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. I cannot imagine being anyplace else.". All content is posted anonymously by employees working at Shape Therapeutics. Shape Therapeutics's key executives include David Huss and 11 others. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. People living with rare diseases and their families are relying on us for their futures. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, Boston, MA 02111. Meet members of our executive team at StrideBio. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Shape Therapeutics, Inc. resistance to cancer treatment. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. 2023 Sarepta Therapeutics, Inc. All rights reserved. As Doug noted, our full year net product revenue was $843.8 million . Get started with your Free Employer Profile, Work Here? PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. Interested in what they do or partnership? Search over 700 Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. | Source: Developer of RNA-targeted therapies intended to treat challenging diseases. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . CAR T-cell therapy to overcome. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases..

Unsolved Murders In Clarksdale Ms, Alex Kompo And Alyssa Still Together 2022, Conspicuous Strategies In Education, Louisiana Dmv Appointment, Omaha Central High School Deceased Alumni, Articles S